P.H., Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop G–25, Atlanta, Georgia 30341–3724, telephone 770/488–8076, FAX 770/488–8282.

Dated: August 24, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–23131 Filed 8–27–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0213]

Asahi Denka Kogyo K.K.; Filing of Food Additive Petition; Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Asahi Denka Kogyo K.K. to indicate that the petitioned additive, phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester is for use as an antioxidant and/or stabilizer in polypropylene homopolymer and copolymers not to exceed 0.25 percent by weight of polypropylene homopolymer and copolymers in contact with food. The previous filing notice indicated that the proposed additive was for use in olefin copolymers and polypropylene in contact with certain food categories.

DATES: Written comments on the petitioner's environmental assessment by September 28, 1998.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane., rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–206), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of June 9, 1997 (62 FR 31433), FDA announced that a food additive petition (FAP 7B4542) had been filed by Asahi Denka Kogyo K.K., Shirahata 5-Chome, Urawa City, Saitama 366, Japan, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the expanded safe use of phosphorous acid, cyclic neopentanetetrayl bis(2,6-di-*tert*-butyl-4-methylphenyl)ester for use: (1) At levels not to exceed 0.25 percent by weight of olefin copolymers complying with § 177.1520 (21 CFR 177.1520) in contact with foods of types I, II, III, IV–B, VI–B, and VIII, as described in Table 1, and under conditions of use B through H, described in Table 2 of § 176.170(c) (21 CFR 176.170(c)), of this chapter, and with food types IV–A, V, VI–A, VI–C, VII–A, and IX, under conditions of use C through G, as described in § 176.170(c), Tables 1 and 2, respectively; and (2) at levels not to exceed 0.10 percent by weight of either olefin copolymers or polypropylene complying with § 177.1520, which may be used only in contact with foods of types IV–A, V, VI–C, VII–A, and IX, under conditions of use H, as described in § 176.170(c) of this chapter, Tables 1 and 2, respectively.

Upon further review of the petition, the agency noted that the data presented in the petition address use of the subject additive only in polypropylene homopolymer and polypropylene copolymers. The agency also noted that the data in the petition in combination with the data for those applications of the additive currently listed in § 178.2010, apply to the use of the subject additive in polypropylene homopolymer and copolymers in contact with all food types under conditions of use B through H as described in Table 2 of § 176.170(c). Based on this information, the petitioner agreed to amend its request. Therefore, FDA is amending the filing notice of June 9, 1997, to state that the petitioner requests that the food additive regulations be amended to permit use of the subject additive in polypropylene homopolymer and copolymers for all food types under conditions of use B through H.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before September 28, 1998, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: August 6, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–23103 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96F–0248]

Life Technologies, Inc.; Filing of Food Additive Petition; Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Life Technologies, Inc., to provide for a change in the extraction requirements for sulphopropyl cellulose ion-exchange resin for the recovery and purification of proteins for food use.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3071.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of July 22, 1996 (61 FR 37905), FDA announced that a food additive petition (FAP 6A4502) had been filed by Life Technologies, Inc., 8400 Helgerman Ct., Gaithersburg, MD 20874 (now, 9800 Medical Center Dr., Rockville, MD 20850). The petition proposed to amend the food additive regulations in § 173.25(b)(5) *Ion-exchange resins* (21 CFR 173.25(b)(5)) to provide for a

change in the temperature and pH limitations for sulphopropyl cellulose ion-exchange resin for the recovery and purification of proteins for food use.

Subsequent to the publication of the filing notice, it was determined that the proposed amendment of the provisions in § 173.25(b)(5) also necessitated an amendment of the provisions in § 173.25(d)(2), the paragraph that provides extraction requirements for the ion-exchange resin. Accordingly, the petitioner amended the petition to request an amendment of § 173.25(d)(2).

Therefore, FDA is amending the filing notice of July 22, 1996, to indicate that the petitioner requests that the food additive regulations be amended to modify the extraction requirements for sulphopropyl cellulose resin in § 173.25(d)(2).

The agency has determined under 21 CFR 25.32(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: August 3, 1998.

George H. Pauli,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–23104 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a joint meeting of the Hematology and Pathology Devices Panel and the Immunology Devices Panel of the Medical Devices Advisory Committee that is scheduled for September 4, 1998. This meeting was announced in the **Federal Register** of August 13, 1998 (63 FR 43401). The amendment is being made to reflect changes in the *Date and Time* and *Procedure* portions of the meeting. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Veronica J. Calvin, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1243.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 13, 1998 (63 FR 43401), FDA announced that a joint meeting of the Hematology and Pathology Devices Panel and the Immunology Devices Panel of the Medical Devices Advisory Committee would be held on September 4, 1998.

On page 43401, in the second column, the ''*Date and Time*'' portion is amended to read as follows:

Date and Time: The meeting will be held on September 4, 1998, 8 a.m. to 3:30 p.m.

On page 43401, in the third column, the ''*Procedure*'' portion is amended to read as follows:

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by August 21, 1998. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 8:45 a.m. * * *.

Dated: August 24, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–23265 Filed 8–26–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0424]

Agency Information Collection Activities; Announcement of OMB Approval; Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of Friday, October 24, 1997 (62 FR 55408), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0376. The approval expires on August 31, 2001.

Dated: August 22, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–23105 Filed 8–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the President's Cancer Panel.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting:

Name of Committee: President's Cancer Panel.

Date: October 6, 1998.

Time: 8:30 AM to 5:30 PM.

Agenda: Quality of Cancer Care/Quality of Life Decision Making Based on Quality of Care Guidelines and Their Impact.

Place: Roswell Park Cancer Institute, Hilleboe Auditorium, Research Studies Center, Elm and Carlton Street, Buffalo, NY 14263.

Contact Person: Maureen O. Wilson, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 4A48, Bethesda, MD 20892.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)